Post-Conference Perspectives: Chronic Lymphocytic Leukemia

EP. 2: Frontline BTK Inhibition in CLL: 7-Year Follow-up Data From RESONATE-2

A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.

By Brad S. Kahl, MD, Washington University School of Medicine

EP. 3: 4-Year Follow-up Data From ELEVATE-TN: Frontline Acalabrutinib in CLL

Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.

By Brad S. Kahl, MD, Washington University School of Medicine

EP. 4: Head-to-Head Analysis of Acalabrutinib Vs Ibrutinib in Previously Treated CLL

Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.

By Brad S. Kahl, MD, Washington University School of Medicine

EP. 5: Optimal Toxicity Management With BTK Inhibitors in CLL

Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.

By Brad S. Kahl, MD, Washington University School of Medicine

EP. 6: Moving the Dial on CLL Management: Sequencing Strategies and Unmet Needs

Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.

By Brad S. Kahl, MD, Washington University School of Medicine

EP. 7: The Evolution of CLL Treatment

Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.

EP. 8: Rationale and Use of BTK Inhibitors as Initial Treatment for CLL

Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.

EP. 9: Frontline BTKi Therapy in CLL: The ELEVATE-TN Study 4-Year Follow-up

A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.

EP. 10: Acalabrutinib vs Ibrutinib: Head-to-Head Data in Previously Treated CLL

Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.

EP. 11: Optimal Treatment Strategies for Chronic Lymphocytic Leukemia

Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.

EP. 12: Looking Toward the Future of CLL Management

Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.